ES2949277T3 - Proceso de preparación de agentes óseos terapéuticos de alta pureza - Google Patents

Proceso de preparación de agentes óseos terapéuticos de alta pureza Download PDF

Info

Publication number
ES2949277T3
ES2949277T3 ES14852866T ES14852866T ES2949277T3 ES 2949277 T3 ES2949277 T3 ES 2949277T3 ES 14852866 T ES14852866 T ES 14852866T ES 14852866 T ES14852866 T ES 14852866T ES 2949277 T3 ES2949277 T3 ES 2949277T3
Authority
ES
Spain
Prior art keywords
mci
radioactive
composition
dotmp
isotope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14852866T
Other languages
English (en)
Spanish (es)
Inventor
Jaime Simon
R Keith Frank
David A Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Igl Pharma Inc
Original Assignee
Igl Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igl Pharma Inc filed Critical Igl Pharma Inc
Application granted granted Critical
Publication of ES2949277T3 publication Critical patent/ES2949277T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
    • G21G1/02—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes in nuclear reactors
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
    • G21G1/001—Recovery of specific isotopes from irradiated targets
    • G21G2001/0094—Other isotopes not provided for in the groups listed above

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Plasma & Fusion (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES14852866T 2013-10-07 2014-10-07 Proceso de preparación de agentes óseos terapéuticos de alta pureza Active ES2949277T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361887603P 2013-10-07 2013-10-07
PCT/US2014/059385 WO2015054173A1 (en) 2013-10-07 2014-10-07 High purity therapeutic bone agents

Publications (1)

Publication Number Publication Date
ES2949277T3 true ES2949277T3 (es) 2023-09-27

Family

ID=52813560

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14852866T Active ES2949277T3 (es) 2013-10-07 2014-10-07 Proceso de preparación de agentes óseos terapéuticos de alta pureza

Country Status (12)

Country Link
US (2) US10172965B2 (OSRAM)
EP (1) EP3054996B1 (OSRAM)
JP (2) JP6787781B2 (OSRAM)
CA (1) CA2926652C (OSRAM)
DK (1) DK3054996T3 (OSRAM)
ES (1) ES2949277T3 (OSRAM)
FI (1) FI3054996T3 (OSRAM)
HU (1) HUE062439T2 (OSRAM)
PL (1) PL3054996T3 (OSRAM)
PT (1) PT3054996T (OSRAM)
SI (1) SI3054996T1 (OSRAM)
WO (1) WO2015054173A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180104366A1 (en) * 2015-05-25 2018-04-19 Isotherapeutics Group, Llc Dotmp kit formulations for radioisotopes
US11369700B2 (en) * 2015-05-25 2022-06-28 IGL Pharma Inc. DOTMP kit formulations for radioisotopes
US11813339B2 (en) 2017-02-08 2023-11-14 Igl Pharma, Inc. Method of use for therapeutic bone agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064633A (en) 1984-06-04 1991-11-12 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes, their formulations and use
US5059412A (en) 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
US4898724A (en) 1984-06-04 1990-02-06 The Dow Chemical Company Organis amine phosphonic acid complexes for the treatment of calcific tumors
US4882142A (en) * 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
MC2260A1 (fr) * 1990-06-18 1993-04-26 Dow Chemical Co Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation
EP1191948A2 (en) 1999-06-11 2002-04-03 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
AU2002364552A1 (en) * 2001-12-13 2003-06-30 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals
CN1741821B (zh) 2002-10-29 2011-08-10 恩根尼公司 用于癌症治疗的组合物
US20040258614A1 (en) * 2003-06-20 2004-12-23 University Of Maryland, Baltimore Microparticles for microarterial imaging and radiotherapy
AR053579A1 (es) 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
JP5199108B2 (ja) 2005-11-14 2013-05-15 ユニヴァーシティー オブ サザン カリフォルニア インテグリン結合小分子
WO2011149844A1 (en) * 2010-05-24 2011-12-01 Iso Therapeutics Group Llc Delivery of high dose therapeutic radioisotopes to bone

Also Published As

Publication number Publication date
HUE062439T2 (hu) 2023-11-28
CA2926652C (en) 2021-07-20
CA2926652A1 (en) 2015-04-16
US10596277B2 (en) 2020-03-24
JP6787781B2 (ja) 2020-11-18
US10172965B2 (en) 2019-01-08
US20160250359A1 (en) 2016-09-01
JP2016532652A (ja) 2016-10-20
SI3054996T1 (sl) 2023-11-30
JP2019123731A (ja) 2019-07-25
US20190083661A1 (en) 2019-03-21
PT3054996T (pt) 2023-08-01
EP3054996B1 (en) 2023-06-21
JP7068222B2 (ja) 2022-05-16
DK3054996T3 (da) 2023-07-10
WO2015054173A1 (en) 2015-04-16
FI3054996T3 (fi) 2023-08-31
EP3054996A1 (en) 2016-08-17
EP3054996A4 (en) 2017-07-05
PL3054996T3 (pl) 2023-09-18

Similar Documents

Publication Publication Date Title
KR100671387B1 (ko) 석회화된 조직을 표적으로 하는, 통증 완화, 뼈 암 치료,및 뼈 표면 조절용 라듐-223의 제조 및 용도
ES2250419T3 (es) Radioterapia.
ES2314977T3 (es) Agentes radioterapeuticos que contienen estaño-117m.
US10596277B2 (en) High purity therapeutic bone agents
WO2011149844A1 (en) Delivery of high dose therapeutic radioisotopes to bone
CA2987242C (en) Dotmp kit formulations for radioisotopes
JP7792746B2 (ja) 治療用骨剤の使用方法
WO2003105762A2 (en) Treating disease using radium-225
Pedraza et al. Genotoxic and cytotoxic damage by the therapeutic radiopharmaceutical [166Dy] Dy/166Ho-EDTMP as in vivo generator system